Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isosorbide diesters + hydrocortisone
- Development stage
- Unknown
- Lead developer
- Sytheon
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Isosorbide diesters + hydrocortisone is a combination therapy investigated for the treatment of atopic dermatitis. The isosorbide diester component, developed by Sytheon, consists of isosorbide di-(linoleate/oleate) (IDL) and isosorbide dicaprylate (IDC), which are fatty acid esters derived from sunflower and coconut oils. These compounds function by strengthening the epidermal barrier, enhancing skin hydration, and regulating keratinocyte differentiation. Additionally, they suppress several pro-inflammatory mediators, including IL-1β, TSLP, and transient receptor potential channels (TRPV3 and TRPA1). Hydrocortisone, a low-potency corticosteroid, is included to manage breakthrough flares and reduce overall skin inflammation. Clinical trials in pediatric and adult populations have demonstrated that this combination can reduce pruritus, improve disease severity scores, and decrease dependence on topical corticosteroids.
- Other names
- isosorbide di-(linoleate/oleate) + isosorbide dicaprylate + hydrocortisoneIDL + IDC + hydrocortisoneHydraSynol IDL + HydraSynol DOI + hydrocortisone
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on isosorbide diesters + hydrocortisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isosorbide diesters + hydrocortisone.